IPO Year: 2026
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/13/2026 | $16.00 | Buy | H.C. Wainwright |
| 3/24/2026 | $24.00 | Overweight | Piper Sandler |
| 3/24/2026 | $20.00 | Overweight | Morgan Stanley |
| 3/24/2026 | Overweight | Cantor Fitzgerald | |
| 3/24/2026 | $30.00 | Buy | Guggenheim |
| 3/24/2026 | $26.00 | Buy | Goldman |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright initiated coverage of Generate Biomedicines with a rating of Buy and set a new price target of $16.00
Piper Sandler initiated coverage of Generate Biomedicines with a rating of Overweight and set a new price target of $24.00
Morgan Stanley initiated coverage of Generate Biomedicines with a rating of Overweight and set a new price target of $20.00
Cantor Fitzgerald initiated coverage of Generate Biomedicines with a rating of Overweight
Guggenheim initiated coverage of Generate Biomedicines with a rating of Buy and set a new price target of $30.00
Goldman initiated coverage of Generate Biomedicines with a rating of Buy and set a new price target of $26.00
8-K - Generate Biomedicines, Inc. (0002100782) (Filer)